Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID‐19 vaccination.

Autor: Kister, Ilya1 (AUTHOR) ilya.kister@nyulangone.org, Curtin, Ryan2 (AUTHOR), Piquet, Amanda L.3 (AUTHOR), Borko, Tyler3 (AUTHOR), Pei, Jinglan4 (AUTHOR), Banbury, Barbara L5 (AUTHOR), Bacon, Tamar E.1 (AUTHOR), Kim, Angie1 (AUTHOR), Tuen, Michael6 (AUTHOR), Velmurugu, Yogambigai2 (AUTHOR), Nyovanie, Samantha2 (AUTHOR), Selva, Sean3 (AUTHOR), Samanovic, Marie I.6 (AUTHOR), Mulligan, Mark J.6 (AUTHOR), Patskovsky, Yury2 (AUTHOR), Priest, Jessica4 (AUTHOR), Cabatingan, Mark4 (AUTHOR), Winger, Ryan C.4 (AUTHOR), Krogsgaard, Michelle2 (AUTHOR) michelle.krogsgaard@nyulangone.org, Silverman, Gregg J.7 (AUTHOR) gregg.silverman@nyulangone.org
Zdroj: Annals of Clinical & Translational Neurology. Jul2024, Vol. 11 Issue 7, p1750-1764. 15p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje